A publicly traded life sciences company that had experienced rapid growth since its’ birth as a start-up needed to rapidly transform from informal practices and a minimal cybersecurity program to a scalable program that could meet several external compliance requirements (starting with SOC2). The Reveal Risk team assembled a deep pharma/life sciences team with prior leaders from several major pharmaceutical companies to drive a rapid but significant controls and program up-lift and readiness exercise.